303 related articles for article (PubMed ID: 30406111)
1. The Role of PI3K in Met Driven Cancer: A Recap.
Hervieu A; Kermorgant S
Front Mol Biosci; 2018; 5():86. PubMed ID: 30406111
[TBL] [Abstract][Full Text] [Related]
2. Multipoint targeting of the PI3K/mTOR pathway in mesothelioma.
Zhou S; Liu L; Li H; Eilers G; Kuang Y; Shi S; Yan Z; Li X; Corson JM; Meng F; Zhou H; Sheng Q; Fletcher JA; Ou WB
Br J Cancer; 2014 May; 110(10):2479-88. PubMed ID: 24762959
[TBL] [Abstract][Full Text] [Related]
3. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer.
Yu L; Wei J; Liu P
Semin Cancer Biol; 2022 Oct; 85():69-94. PubMed ID: 34175443
[TBL] [Abstract][Full Text] [Related]
4. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
Burris HA
Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
[TBL] [Abstract][Full Text] [Related]
5. The role of RICTOR downstream of receptor tyrosine kinase in cancers.
Jebali A; Dumaz N
Mol Cancer; 2018 Feb; 17(1):39. PubMed ID: 29455662
[TBL] [Abstract][Full Text] [Related]
6. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
7. mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment.
Mafi S; Mansoori B; Taeb S; Sadeghi H; Abbasi R; Cho WC; Rostamzadeh D
Front Immunol; 2021; 12():774103. PubMed ID: 35250965
[TBL] [Abstract][Full Text] [Related]
8. PI3K/Akt/mTOR Signaling Pathway: Role in Esophageal Squamous Cell Carcinoma, Regulatory Mechanisms and Opportunities for Targeted Therapy.
Luo Q; Du R; Liu W; Huang G; Dong Z; Li X
Front Oncol; 2022; 12():852383. PubMed ID: 35392233
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Potential of PI3K/AKT/mTOR Pathway in Gastrointestinal Stromal Tumors: Rationale and Progress.
Duan Y; Haybaeck J; Yang Z
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33066449
[TBL] [Abstract][Full Text] [Related]
10. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
Marquard FE; Jücker M
Biochem Pharmacol; 2020 Feb; 172():113729. PubMed ID: 31785230
[TBL] [Abstract][Full Text] [Related]
11. PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application.
Xia P; Xu XY
Am J Cancer Res; 2015; 5(5):1602-9. PubMed ID: 26175931
[TBL] [Abstract][Full Text] [Related]
12. PI3K/AKT inhibition induces compensatory activation of the MET/STAT3 pathway in non-small cell lung cancer.
Bian C; Liu Z; Li D; Zhen L
Oncol Lett; 2018 Jun; 15(6):9655-9662. PubMed ID: 29928341
[TBL] [Abstract][Full Text] [Related]
13. The Role of mTOR Signaling as a Therapeutic Target in Cancer.
Popova NV; Jücker M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572326
[TBL] [Abstract][Full Text] [Related]
14. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
15. Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling.
Grunt TW; Mariani GL
Curr Cancer Drug Targets; 2013 Feb; 13(2):188-204. PubMed ID: 23215720
[TBL] [Abstract][Full Text] [Related]
16. Recent Updates on the Involvement of PI3K/AKT/mTOR Molecular Cascade in the Pathogenesis of Hyperproliferative Skin Disorders.
Mercurio L; Albanesi C; Madonna S
Front Med (Lausanne); 2021; 8():665647. PubMed ID: 33996865
[TBL] [Abstract][Full Text] [Related]
17. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
18. Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer.
Evangelisti C; Chiarini F; Paganelli F; Marmiroli S; Martelli AM
Biochim Biophys Acta Mol Cell Res; 2020 Apr; 1867(4):118635. PubMed ID: 31884070
[TBL] [Abstract][Full Text] [Related]
19. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer.
Yip PY
Transl Lung Cancer Res; 2015 Apr; 4(2):165-76. PubMed ID: 25870799
[TBL] [Abstract][Full Text] [Related]
20. The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma.
Matsuoka T; Yashiro M
Cancers (Basel); 2014 Jul; 6(3):1441-63. PubMed ID: 25003395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
